Type to search

CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) | Pharmtech Focus
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units | Pharmtech Focus